← Back
NeuroTrials.ai
Neurology Clinical Trial Database

PACIFIC

Bexicaserin for the treatment of seizures in developmental and epileptic encephalopathies: A phase 1b/2a trial (PACIFIC)

Year of Publication: 2026

Authors: Dlugos DJ, Scheffer IE, French JA, ..., and the LP352-201 Study Investigators

Journal: Epilepsia

Citation: Epilepsia. 2026;67(2):646-659.

Link: https://doi.org/10.1111/epi.18689


Clinical Question

Does bexicaserin, a selective 5-HT2C receptor superagonist, safely reduce seizure frequency in adolescents and adults with developmental and epileptic encephalopathies of diverse etiologies?

Bottom Line

In this phase 1b/2a trial, bexicaserin was well tolerated and produced clinically meaningful reductions in countable motor seizures (-59.8% vs -17.4% with placebo) across diverse DEE subtypes, supporting the novel inclusive trial design and progression to phase 3 development.

Major Points

  • Bexicaserin reduced median countable motor seizure frequency by -59.8% vs -17.4% with placebo across a heterogeneous DEE population.
  • Efficacy was consistent across DEE subtypes: Dravet syndrome -74.6%, Lennox-Gastaut syndrome -50.8%, DEE Other -65.5%.
  • Responder analysis (≥50% reduction in countable motor seizures): 60.0% with bexicaserin vs 33.3% with placebo.
  • Drug-related TEAEs occurred in 65.1% (bexicaserin) vs 33.3% (placebo); somnolence was the most frequent reason for discontinuation.
  • Discontinuation rates: 16.3% during titration and 4.7% during maintenance due to TEAEs.
  • 85.7% of maintenance participants tolerated the highest dose (12 mg TID); 77.1% sustained it through maintenance.
  • The inclusive trial design enrolling DS, LGS, and 'DEE Other' patients may serve as a model to expand access to investigational therapies for previously excluded DEE populations.
  • Bexicaserin has progressed to phase 3 development based on these findings.

Design

Study Type: Phase 1b/2a randomized, double-blind, placebo-controlled, parallel-group, dose-escalation clinical trial

Randomization: 1

Blinding: Double-blind (investigators, site staff, participants, caregivers, monitors, sponsor study management, and CRO all blinded)

Allocation: 4:1 bexicaserin:placebo, stratified by DEE subtype (DS, LGS, DEE Other) via Interactive Web Response System

Enrollment Period: March 3, 2022 to November 20, 2023

Follow-up Duration: 5-week screening/baseline + 15-day flexible uptitration + 60-day maintenance + 5-15-day taper + 30-day follow-up (optional 52-week open-label extension)

Centers: 34

Countries: United States, Australia

Sample Size: 52

Analyzed: 44

Analysis: Safety set: all participants who received ≥1 dose (n=52). Full analysis set: participants who completed titration and had ≥1 postbaseline seizure measurement during maintenance (n=44). Wilcoxon-Mann-Whitney test for seizure frequency percentage change; Fisher exact test for categorical proportions; post hoc two-sample t-test for change from baseline in countable motor seizures.

Power Calculation: No formal sample size calculation; planned enrollment of 50 (10 DS, 10 LGS, 30 DEE Other) given exploratory phase 1b/2a design

Registration: NCT05364021 (registered March 22, 2022)


Inclusion Criteria

  • Age ≥12 and ≤65 years
  • Diagnosis of DEE (Dravet syndrome, Lennox-Gastaut syndrome, or DEE Other)
  • Average ≥4 countable motor seizures per 4-week period during the 12 weeks before screening
  • ≥4 countable motor seizures during the 4-week screening period (≥2 in first 14 days and ≥2 in second 14 days)
  • Taking 1-4 concomitant antiseizure medications at stable doses for ≥4 weeks before screening (30 days for cannabidiol-based drugs)
  • Not seizure-free for >21 consecutive days during baseline

Exclusion Criteria

  • Current or prior use of fenfluramine or lorcaserin
  • Topiramate use (unless stable for ≥6 months before screening)
  • Use of anorectic agents, monoamine oxidase inhibitors, or serotonin agonists/antagonists
  • History of cardiovascular or cerebrovascular disease (e.g., pulmonary arterial hypertension, cardiac valvulopathy, myocardial infarction, or stroke)

Baseline Characteristics

CharacteristicPlacebo (n=9)Bexicaserin (n=43)Overall (N=52)
Mean Age (SD)26.7 (7.7)23.8 (9.6)24.3 (9.3)
Median Age232323
Age Range19-4112-5512-55
Male n (%)7 (77.8)21 (48.8)28 (53.8)
Female n (%)2 (22.2)22 (51.2)24 (46.2)
Asian n (%)2 (22.2)3 (7.0)
Black or African American n (%)01 (2.3)
Native Hawaiian or Other Pacific Islander n (%)02 (4.7)
DEE Subtypes EnrolledLGS n=29; DS n=4; DEE Other n=19
Seizure Types ≥20%Generalized tonic-clonic 63.5%, Absence 53.8%, Tonic 53.8%, Focal 48.1%, Myoclonic 42.3%, Focal-to-bilateral tonic-clonic 23.1%, Atonic 21.2%
Median Baseline Countable Motor Seizures (28-day, range)DS 31.5 (18-70); LGS 51.5 (5-389); DEE Other 20.8 (6-325)
Common Concomitant ASMsClobazam, valproate, levetiracetam, cannabidiol, lamotrigine

Arms

FieldBexicaserinControl
N439
InterventionOral bexicaserin liquid (3 mg/mL) administered orally or via G-tube/PEG; flexible uptitration at 6, 9, or 12 mg three times daily (5 days each) followed by 60-day maintenance on highest tolerated dose; doses administered ≥6 h apartMatching placebo oral solution administered on same schedule as bexicaserin
Duration15-day uptitration + 60-day maintenance (optional 52-week open-label extension)15-day uptitration + 60-day maintenance

Outcomes

OutcomeTypeControlInterventionHR / OR / RRP-value
Co-primary endpoints: (1) incidence and severity of treatment-emergent adverse events (TEAEs); (2) median percentage change from baseline in observed countable motor seizure frequency during the treatment period (titration and maintenance)PrimaryMedian -17.4% change in countable motor seizure frequencyMedian -59.8% change in countable motor seizure frequency
Secondary33.3% (3/9)60.0%
Secondary
Secondary30/35 (85.7%) of maintenance participants reached 12 mg TID; 27/35 (77.1%) tolerated 12 mg TID through maintenance
Safety3/9 (33.3%)28/43 (65.1%)
Safety7/43 (16.3%)
Safety2/43 (4.7%)
SomnolenceAdverse
65.1% (28/43)Adverse
33.3% (3/9)Adverse
16.3% (7/43) bexicaserinAdverse
4.7% (2/43) bexicaserinAdverse

Subgroup Analysis

Efficacy by DEE subtype: Dravet syndrome -74.6%, Lennox-Gastaut syndrome -50.8%, DEE Other -65.5% median reduction in countable motor seizures. Consistent benefit observed across etiologically heterogeneous DEE population.


Criticisms

  • Small sample size (N=52) with imbalanced randomization (4:1) limits statistical power and precision of efficacy estimates.
  • No formal hypothesis testing performed; reported p-values are nominal and not adjusted for multiple testing.
  • Open-label-style exploratory design with no formal sample size calculation.
  • Heterogeneous DEE Other group includes diverse etiologies, complicating interpretation of pooled efficacy.
  • Short maintenance period (60 days) limits assessment of durability and long-term safety; longer-term data depend on the 52-week OLE.
  • Exclusion of patients with cardiovascular/cerebrovascular disease limits generalizability given common DEE comorbidities.
  • Caregiver-reported seizure diaries are subject to recall and counting bias, particularly for difficult-to-count seizures.

Funding

Longboard Pharmaceuticals (now part of H. Lundbeck A/S)

Based on: PACIFIC (Epilepsia, 2026)

Authors: Dlugos DJ, Scheffer IE, French JA, ..., and the LP352-201 Study Investigators

Citation: Epilepsia. 2026;67(2):646-659.

Content summarized and formatted by NeuroTrials.ai.